X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (175) 175
humans (147) 147
magnitude (113) 113
female (94) 94
male (90) 90
adult (51) 51
analysis (39) 39
adolescent (38) 38
middle aged (37) 37
young adult (31) 31
aged (30) 30
research (30) 30
neurosciences (29) 29
children (28) 28
vibration (26) 26
animals (25) 25
child (25) 25
article (24) 24
health aspects (24) 24
care and treatment (23) 23
low-magnitude (23) 23
studies (22) 22
oncology (21) 21
psychology (20) 20
usage (19) 19
vibration - therapeutic use (18) 18
exercise (16) 16
osteoporosis (16) 16
psychiatry (16) 16
risk (16) 16
risk factors (16) 16
medicine & public health (15) 15
physiology (15) 15
postmenopausal women (15) 15
prevention (15) 15
intervention (14) 14
radiology, nuclear medicine & medical imaging (14) 14
rehabilitation (14) 14
whole-body vibration (14) 14
alcohol (13) 13
alcohol use (13) 13
behavioral sciences (13) 13
clinical neurology (13) 13
orthopedics (13) 13
physiological aspects (13) 13
psychology, clinical (13) 13
psychology, experimental (13) 13
students (13) 13
taste (13) 13
treatment outcome (13) 13
bones (12) 12
cancer (12) 12
density (12) 12
endocrinology & metabolism (12) 12
food science & technology (12) 12
magnitude estimation (12) 12
morbidity (12) 12
muscle strength (12) 12
college students (11) 11
dentistry (11) 11
dentistry, oral surgery & medicine (11) 11
disease (11) 11
mortality (11) 11
psychophysics (11) 11
substance abuse (11) 11
surveys and questionnaires (11) 11
time factors (11) 11
aged, 80 and over (10) 10
behavior (10) 10
bone density (10) 10
child, preschool (10) 10
diagnosis (10) 10
individual-differences (10) 10
magnetic resonance imaging (10) 10
multidisciplinary sciences (10) 10
reproducibility of results (10) 10
adaptation (9) 9
cognition (9) 9
cortical bone (9) 9
epidemiology (9) 9
frequency (9) 9
low-level (9) 9
mechanical signals (9) 9
methods (9) 9
mineral density (9) 9
pain (9) 9
performance (9) 9
quality of life (9) 9
rats (9) 9
research article (9) 9
responses (9) 9
sensitivity (9) 9
stimulation (9) 9
surgery (9) 9
time (9) 9
abridged index medicus (8) 8
bone (8) 8
clinical trials (8) 8
mathematical concepts (8) 8
mathematics (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA ONCOLOGY, ISSN 2374-2437, 08/2019, Volume 5, Issue 8, pp. 1188 - 1194
ImportanceThe American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have independently published value frameworks.... 
ASCO | COST | ONCOLOGY | ANTICANCER THERAPIES | TIME | ESMO-MAGNITUDE | CANCER
Journal Article
Annals of Oncology, ISSN 0923-7534, 2016, Volume 27, Issue 11, pp. 2134 - 2136
For utilising the ESMO-MCBS in pre-reimbursement HTA an adapted version is proposed: prioritized use of the patient-relevant endpoint OS and QoL; use of point... 
CLINICAL BENEFIT SCALE | MAGNITUDE | MEDICINES | ONCOLOGY | HEALTH-CARE-SYSTEMS | Index Medicus
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 11/2017, Volume 27, Issue 9, pp. 1872 - 1876
INTRODUCTIONIn ovarian cancer, it is uncertain which chemotherapy regimen is more clinically effective and cost-effective for the treatment of recurrence;... 
Costs of drugs | Randomized phase 3 trials | Recurrent advanced ovarian cancer | ESMO-MCBS | Second-line therapy | CLINICAL BENEFIT SCALE | SURVIVAL | PEGYLATED LIPOSOMAL DOXORUBICIN | PERSPECTIVE | CARE | OBSTETRICS & GYNECOLOGY | MAGNITUDE | ONCOLOGY | THERAPIES | ECONOMICS | Drug Costs | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neoplasm Recurrence, Local - economics | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - administration & dosage | Dioxoles - economics | Polyethylene Glycols - economics | Trabectedin | Neoplasms, Glandular and Epithelial - economics | Dioxoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - economics | Doxorubicin - analogs & derivatives | Female | Randomized Controlled Trials as Topic - economics | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Paclitaxel - economics | Deoxycytidine - administration & dosage | Tetrahydroisoquinolines - economics | Carboplatin - administration & dosage | Doxorubicin - economics | Survival Rate | Tetrahydroisoquinolines - administration & dosage | Deoxycytidine - economics | Carboplatin - economics | Antineoplastic Agents - economics | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Clinical Trials, Phase III as Topic - economics | Ovarian Neoplasms - economics | European Union | Cost-Benefit Analysis | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Journal of Managed Care and Specialty Pharmacy, ISSN 2376-0540, 06/2017, Volume 23, Issue 6, pp. S6 - S12
The debate around value in oncology drug selection has been prominent in recent years, and several professional bodies have furthered this debate by advocating... 
CLINICAL BENEFIT SCALE | SURVIVAL | POPULATION | MAGNITUDE | COST | STATES | CANCER-TREATMENTS | HEALTH CARE SCIENCES & SERVICES | PHARMACOLOGY & PHARMACY | HEALTH | EUROPEAN-SOCIETY | AMERICAN SOCIETY
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2018, Volume 110, Issue 10, pp. 1142 - 1143
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 10/2018, Volume 110, Issue 10
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 04/2019, Volume 20, Issue 4, pp. E193 - E193
Journal Article
The Lancet Oncology, ISSN 1470-2045, 04/2019, Volume 20, Issue 4, pp. e192 - e192
Journal Article
Quality of Life Research, ISSN 0962-9343, 1/2018, Volume 27, Issue 1, pp. 59 - 74
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2018, Volume 24, Issue 20, pp. 4968 - 4975
Purpose: Despite development of clinical "value frameworks" by national and international groups, there remains no generally accepted method to summarize... 
LENVATINIB | MAGNITUDE | BENEFIT | ONCOLOGY | ONCOLOGY VALUE FRAMEWORK | VERSION | COMMON TERMINOLOGY CRITERIA | BURDEN | AMERICAN SOCIETY | ADVERSE EVENTS | PATIENT-REPORTED OUTCOMES
Journal Article
Frontiers in Human Neuroscience, ISSN 1662-5161, 05/2015, Volume 9, Issue May, pp. 304 - 304
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.